share_log

Press Release: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

Press Release: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

新闻稿:彪马生物技术公司将主持电话会议,讨论2020年第四季度和全年财务业绩
Dow Jones Newswires ·  2021/02/12 05:29

Press Release: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

新闻稿:彪马生物技术公司将主持电话会议,讨论2020年第四季度和全年财务业绩

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

彪马生物技术公司将主持电话会议,讨论2020年第四季度和全年财务业绩


LOS ANGELES--(BUSINESS WIRE)--February 11, 2021--

洛杉矶--(美国商业新闻网)--2021年2月11日--

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth quarter and full year 2020 financial results.

彪马生物技术公司(纳斯达克市场代码:PBYI)是一家生物制药公司,该公司将于美国东部时间下午1:30主持电话会议。太平洋标准时间/下午4:30美国东部时间2021年2月25日(星期四),在发布2020年第四季度和全年财务业绩后。

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma's website for 90 days.

拨打1-877-709-8150(国内)或1-201-689-8354(国际)可拨打该电话。请至少提前10分钟拨打电话,并通知接线员您想参加“彪马生物技术电话会议”。电话会议和演示幻灯片的现场网络直播可以在彪马生物技术公司网站的投资者栏目上获得,网址是:http://www.pumabiotechnology.com.。电话会议的重播将在通话结束大约一小时后播放,并将在彪马的网站上存档90天。

About Puma Biotechnology

关于彪马生物技术

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX(R) (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

彪马生物技术公司是一家生物制药公司,专注于创新产品的开发和商业化,以加强癌症治疗。彪马In-授权PB272(口服奈拉替尼)、PB272(奈拉替尼静脉注射)和PB357的全球开发和商业化权利。在基于曲妥珠单抗的辅助治疗之后,neratinib口服于2017年被美国食品和药物管理局(FDA)批准用于HER2过度表达/放大的早期乳腺癌成年患者的扩展辅助治疗,并在美国以NERLYNX(R)(Neratinib)片剂的形式销售。2020年2月,NERLYNX还被FDA批准与卡培他滨联合用于治疗晚期或转移性HER2阳性乳腺癌的成年患者,这些患者之前在转移环境中接受了两种或两种以上基于HER2的抗化疗方案。NERLYNX于2018年获得欧盟委员会的营销授权,可以延长对患有早期激素受体阳性HER2过度表达/放大的乳腺癌的成年患者的辅助治疗,这些患者距离之前完成基于曲妥珠单抗的辅助治疗不到一年。NERLYNX是彪马生物技术公司的注册商标。

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

欲了解有关彪马生物技术公司的更多信息,请访问网站www.PumabioTechnology.com。

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005729/en/

在business wire.com上查看源代码版本:https://www.businesswire.com/news/home/20210211005729/en/

CONTACT: Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

联系人:彪马生物技术公司艾伦·H·奥尔巴赫(Alan H.Auerbach)或玛丽安·奥哈尼辛(Mariann Ohanesian)电话:+1 424 248 6500

info@pumabiotechnology.com

邮箱:info@pumabiotechnology ology.com

ir@pumabiotechnology.com

邮箱:ir@umabioTechnology.com

David Schull or Maggie Beller, Russo Partners, +1 212 845 4200

Russo Partners公司大卫·舒尔或玛吉·贝勒电话:+1212845 4200

david.schull@russopartnersllc.com

邮箱:david.schull@russopartnersllc.com

maggie.beller@russopartnersllc.com

邮箱:maggie.beller@russopartnersllc.com

(END) Dow Jones Newswires

(完)道琼通讯社

February 11, 2021 16:29 ET (21:29 GMT)

2021年2月11日美国东部时间16:29(格林尼治标准时间21:29)

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发